Evidence map›Paper›PMID 24526309›Full record

ArticleNeuro-oncology2014

The potential of theragnostic ¹²⁴I-8H9 convection-enhanced delivery in diffuse intrinsic pontine glioma.

Neal Luther, Zhiping Zhou, Pat Zanzonico, Nai-Kong Cheung, John Humm, Mark A Edgar, Mark M Souweidane

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed.

  1. Antitumor efficacy and safety of locoregional [European journal of nuclear medicine and molecular imaging · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Theranostic Intratumoral Convection-Enhanced Delivery ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024
    Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Theragnostic Aspects and Radioimmunotherapy in Pediatric Tumors.International journal of molecular sciences · 2020
    Review
  13. B7-H3-targeted Radioimmunotherapy of Human Cancer.Current medicinal chemistry · 2020
    Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. PARP-1-Targeted Radiotherapy in Mouse Models of Glioblastoma.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2018
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Neal LutherDepartment of Neurological Surgery, Weill Medical College of Cornell University, New York, New York (N.L., Z.Z.); Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York (P.Z., J.H.); Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York (N.-K.C.); Department of Pathology, Emory University, Atlanta, Georgia (M.A.E.); Department of Neurological Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York (M.M.S.).
Zhiping ZhouDepartment of Neurological Surgery, Weill Medical College of Cornell University, New York, New York (N.L., Z.Z.); Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York (P.Z., J.H.); Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York (N.-K.C.); Department of Pathology, Emory University, Atlanta, Georgia (M.A.E.); Department of Neurological Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York (M.M.S.).
Pat ZanzonicoDepartment of Neurological Surgery, Weill Medical College of Cornell University, New York, New York (N.L., Z.Z.); Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York (P.Z., J.H.); Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York (N.-K.C.); Department of Pathology, Emory University, Atlanta, Georgia (M.A.E.); Department of Neurological Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York (M.M.S.).
Nai-Kong CheungDepartment of Neurological Surgery, Weill Medical College of Cornell University, New York, New York (N.L., Z.Z.); Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York (P.Z., J.H.); Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York (N.-K.C.); Department of Pathology, Emory University, Atlanta, Georgia (M.A.E.); Department of Neurological Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York (M.M.S.).
John HummDepartment of Neurological Surgery, Weill Medical College of Cornell University, New York, New York (N.L., Z.Z.); Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York (P.Z., J.H.); Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York (N.-K.C.); Department of Pathology, Emory University, Atlanta, Georgia (M.A.E.); Department of Neurological Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York (M.M.S.).
Mark A EdgarDepartment of Neurological Surgery, Weill Medical College of Cornell University, New York, New York (N.L., Z.Z.); Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York (P.Z., J.H.); Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York (N.-K.C.); Department of Pathology, Emory University, Atlanta, Georgia (M.A.E.); Department of Neurological Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York (M.M.S.).
Mark M SouweidaneDepartment of Neurological Surgery, Weill Medical College of Cornell University, New York, New York (N.L., Z.Z.); Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York (P.Z., J.H.); Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York (N.-K.C.); Department of Pathology, Emory University, Atlanta, Georgia (M.A.E.); Department of Neurological Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York (M.M.S.).

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

backgroundReasons for failure in prior human glioma convection-enhanced delivery (CED) clinical trials remain unclear. Concentration-dependent volume of distribution (Vd) measurement of CED-infused agents in the human brain is challenging and highlights a potential technical shortcoming. Activity of iodine isotope 124 ((124)I ) in tissue can be directly measured in vivo with high resolution via PET. With the potential therapeutic utility of radioimmunotherapy, we postulate (124)I conjugated to the antiglioma monoclonal antibody 8H9 may serve as a "theragnostic" agent delivered via CED to diffuse intrinsic pontine glioma.

methodsFifteen rats underwent CED of 0.1-1.0 mCi of (131)I-8H9 to the pons for toxicity evaluation. Six additional rats underwent CED of 10 µCi of (124)I-8H9 to the pons for dosimetry, with serial microPET performed for 1 week. Two primates underwent CED of gadolinium-albumin and 1.0 mCi of (124)I-8H9 to the pons for safety and dosimetry analysis. Serial postoperative PET, blood, and CSF radioactivity counts were performed.

resultsOne rat (1.0 mCi (131)I-8H9 infusion) suffered toxicity necessitating early sacrifice. PET analysis in rats yielded a pontine absorbed dose of 37 Gy/mCi. In primates, no toxicity was observed, and absorbed pontine dose was 3.8 Gy/mCi. Activity decreased 10-fold with 48 h following CED in both animal models. Mean Vd was 0.14 cc(3) (volume of infusion [Vi] to Vd ratio = 14) in the rat and 6.2 cc(3) (Vd/Vi = 9.5) in primate.

conclusionThe safety and feasibility of (124)I dosimetry following CED via PET is demonstrated, establishing a preclinical framework for a trial evaluating CED of (124)I-8H9 for diffuse intrinsic pontine glioma.

Indexed as

RadioimmunotherapyAnimalsAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedBrain Stem NeoplasmsConvectionGliomaHumansIodine RadioisotopesMacaca fascicularisMalePositron-Emission TomographyRadiometryRats8H9 monoclonal antibodyAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedIodine Radioisotopesantibodybrain stemgliomainterstitialPETradioimmunotherapy

Identifiers

PMID24526309
PMCPMC4022223

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.